HSPG2 and ischemic stroke: The therapeutic potential of exogenously administered perlecan domain V in a severe pre-clinical ischemic stroke model (photothrombotic and intraluminal MCAO) is essentially dependent on how quickly the first dose of perlecan domain V is administered after ischemic stroke induction.